Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Non-small-cell lung cancer (NSCLC) often spreads beyond the lungs by the time it is diagnosed, making surgical removal impossible. In recent decades, cytotoxic chemotherapy drugs have become the primary treatment, particularly for patients with NSCLC who do not have mutations in the EGFR, ALK, and ROS genes. The prognosis for lung cancer is generally poor, with an overall 5-year survival rate of only 9–13%. As a result, treating advanced NSCLC remains a critical medical challenge. Recent research has highlighted a significant connection between the gut-lung axis microecology and malignant tumors. It appears that intestinal probiotics may play a role in inhibiting tumor developm…